Skyclarys Access Battle in Ireland | Ireland News

Friedreich’s ataxia patients are fighting for access to the breakthrough drug Skyclarys, approved in the U.S. and Europe, which could slow disease progression by up to 55%. Ireland’s HSE has refused to fund it due to uncertainty over its effectiveness, sparking fierce political pressure from both parties and patient advocates. Biogen is being urged to collaborate with the HSE and consider a compassionate access program before the August 25th meeting — as families await a lifeline that may not cure, but could dramatically improve their quality of life. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/aedff387ab617632